A total of 400 patients with 5 types of allergic conjunctivitis were divided into control and treatment groups (n=200 each). The control group took conventional medication while the treatment group received sublingual immunotherapy (SLIT). After 2-year treatment, for perennial allergic, seasonal allergic or atopic angle conjunctivitis, the decreases of medication score in the treatment group were all significantly more than those in the control group (all P<0.01). No serious adverse event was reported. SLIT with Dermatophagodies farianae drops is both safe and effective in patients with perennial allergic, seasonal allergic and atopic angle conjunctivitis. However its efficacies for vernal and giant papillary conjunctivitis require further studies.
Key words:
Conjunctivitis, allergic; Immunotherapy
Abstract Background The Skeletal Muscle Index (SMI) is an objective indicator for evaluating the nutritional status in malignant tumors. The baseline nutritional status may affect the efficacy and prognosis of targeted anti-tumor therapy, and growth factor tyrosine kinase inhibitors often lead to drug-related sarcopenia. Fruquintinib has been approved for metastatic colorectal cancer. In this study, we analyzed the prognostic value of baseline SMI in metastatic colorectal cancer treated with fruquintinib, and observed the incidence of SMI reduction after fruquintinib treatment to evaluate its impact on prognosis. Methods A retrospective multi-center analysis of metastatic colorectal cancer patients treated with fruquintinib in eight medical centers in China was performed. The muscle area of the third lumbar spine was evaluated, the baseline SMI and post-treatment SMI were calculated separately. The correlation with survival was analyzed. Results The median PFS of 105 patients was 4.2 months (95% CI, 3.7 months to 4.9 months), and the median OS was 10.2 months (95% CI, 9.0 months to 12.7 months). The baseline SMI before fruquintinib therapy was significantly correlated with OS (P = 0.0077). Multivariate analysis demonstrated that the baseline SMI was an independent prognostic factor for OS (P = 0.005). Twenty-eight point eight seven percent (28.87%) patients experienced sarcopenia after oral administration of fruquintinib. However, there was no significant difference in OS between the SMI reduced group and the SMI nonreduced group after treatment with fruquintinib. Conclusion The baseline SMI was an independent prognostic factor for OS and it could affect the survival of patients treated with fruquintinib in metastatic colorectal cancer. Although fruquintinib can cause sarcopenia, there is no correlation between post-treatment SMI changes and survival.
The Skeletal Muscle Index (SMI) serves as an objective metric for assessing nutritional status in patients with malignant tumors. Research has found baseline nutritional status can influence both the efficacy and prognosis of targeted anti-tumor therapies, with growth factor tyrosine kinase inhibitors frequently inducing drug-related sarcopenia. Fruquintinib has received approval for the treatment of metastatic colorectal cancer. This study examines the prognostic significance of baseline SMI in patients with metastatic colorectal cancer undergoing treatment with fruquintinib. Additionally, the study investigates the incidence of SMI reduction following fruquintinib therapy to assess its impact on patient prognosis. A retrospective multicenter study was conducted to analyze patients with metastatic colorectal cancer who received fruquintinib treatment across eight medical centers in Eastern China. The muscle area at the third lumbar vertebra was assessed, and both baseline and post-treatment SMI values were calculated independently. The relationship between SMI and patient survival was subsequently examined. The median progression-free survival (PFS) for the cohort of 105 patients was 4.2 months (95% CI, 3.7 to 4.9 months), while the median overall survival (OS) was 10.2 months (95% CI, 9.0 to 12.7 months). Notably, the baseline SMI prior to the initiation of fruquintinib therapy exhibited a significant correlation with OS (P = 0.0077). Multivariate analysis indicated that baseline SMI serves as an independent prognostic factor for OS (P = 0.005). Furthermore, after Propensity Score Matching (PSM) analysis, there was still a significant correlation between baseline SMI and OS. Among the patients, 28.87% developed sarcopenia following oral administration of fruquintinib. However, no statistically significant difference in OS was observed between the group with reduced SMI and the group without SMI reduction after treatment with fruquintinib. The baseline SMI was identified as an independent prognostic factor for OS and may influence the survival outcomes of patients with metastatic colorectal cancer undergoing treatment with fruquintinib. Despite the potential of fruquintinib to induce sarcopenia, no significant correlation was observed between changes in SMI following treatment and patient survival.
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)